HealthEquity, Inc.

Valuation Analysis

About the Company

HealthEquity, Inc. en bref

HealthEquity, Inc. (HQY) is currently trading at 74,28 € with a market capitalization of 6,2 Md €. The trailing P/E ratio stands at 31.91x, with a forward P/E of 15.52x. The 52-week range spans from 63,43 € to 92,93 €; the current price is 20.1% below the yearly high. Year-over-year revenue growth stands at +7.2%. The net profit margin stands at 17.25%.

💰 Dividende

HealthEquity, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

16 analystes évaluent HealthEquity, Inc. (HQY) au consensus : Acheter. L'objectif de cours moyen est de 100,74 €, soit un potentiel de +35.62% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 76,72 € à 117,69 €.

HealthEquity, Inc. : la thèse d'investissement en détail

HealthEquity, Inc. (HQY) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 34.4% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 70.68%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 17.25%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valorisation en contexte

The PEG ratio at 1.23 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 15.52x is meaningfully below the trailing 31.91x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 35.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.54%).

Trading Data

Related Stocks in the Same Sector

Where can I buy HealthEquity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.